Search Results - "DUARTE, R. F"

Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report by Passweg, J R, Baldomero, H, Bader, P, Bonini, C, Duarte, R F, Dufour, C, Gennery, A, Kröger, N, Kuball, J, Lanza, F, Montoto, S, Nagler, A, Snowden, J A, Styczynski, J, Mohty, M

“…Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record…”
Get full text

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually by Passweg, J R, Baldomero, H, Bader, P, Bonini, C, Cesaro, S, Dreger, P, Duarte, R F, Dufour, C, Kuball, J, Farge-Bancel, D, Gennery, A, Kröger, N, Lanza, F, Nagler, A, Sureda, A, Mohty, M

“…A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by…”
Get full text

Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants by Passweg, J R, Baldomero, H, Bader, P, Bonini, C, Cesaro, S, Dreger, P, Duarte, R F, Dufour, C, Falkenburg, J H F, Farge-Bancel, D, Gennery, A, Kröger, N, Lanza, F, Nagler, A, Sureda, A, Mohty, M

“…A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers in 48 countries to the…”
Get full text

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation by Passweg, J R, Baldomero, H, Peters, C, Gaspar, H B, Cesaro, S, Dreger, P, Duarte, R F, Falkenburg, J H F, Farge-Bancel, D, Gennery, A, Halter, J, Kröger, N, Lanza, F, Marsh, J, Mohty, M, Sureda, A, Velardi, A, Madrigal, A

“…In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT (HSCT) in 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) in…”
Get full text

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation by Mohty, M, Hübel, K, Kröger, N, Aljurf, M, Apperley, J, Basak, G W, Bazarbachi, A, Douglas, K, Gabriel, I, Garderet, L, Geraldes, C, Jaksic, O, Kattan, M W, Koristek, Z, Lanza, F, Lemoli, R M, Mendeleeva, L, Mikala, G, Mikhailova, N, Nagler, A, Schouten, H C, Selleslag, D, Suciu, S, Sureda, A, Worel, N, Wuchter, P, Chabannon, C, Duarte, R F

“…Autologous haematopoietic SCT with PBSCs is regularly used to restore BM function in patients with multiple myeloma or lymphoma after myeloablative…”
Get full text

JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement by Snowden, J A, McGrath, E, Duarte, R F, Saccardi, R, Orchard, K, Worel, N, Kuball, J, Chabannon, C, Mohty, M

“…Blood and marrow transplantation (BMT) is a complex and evolving medical speciality that makes substantial demands on healthcare resources. To meet a…”
Get full text

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation by Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Dignan, F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Okamoto, S, Pagliuca, A, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, Duarte, R F, Carreras, E

“…Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life threatening complication that can develop after…”
Get full text

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation by Baron, F, Labopin, M, Blaise, D, Lopez-Corral, L, Vigouroux, S, Craddock, C, Attal, M, Jindra, P, Goker, H, Socié, G, Chevallier, P, Browne, P, Sandstedt, A, Duarte, R F, Nagler, A, Mohty, M

“…The impact of in vivo T-cell depletion on transplantation outcomes in patients transplanted with reduced-intensity conditioning (RIC) remains controversial…”
Get full text

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) by Mohty, M, Malard, F, Abecassis, M, Aerts, E, Alaskar, A S, Aljurf, M, Arat, M, Bader, P, Baron, F, Bazarbachi, A, Blaise, D, Ciceri, F, Corbacioglu, S, Dalle, J-H, Duarte, R F, Fukuda, T, Huynh, A, Masszi, T, Michallet, M, Nagler, A, NiChonghaile, M, Pagluica, T, Peters, C, Petersen, F B, Richardson, P G, Ruutu, T, Savani, B N, Wallhult, E, Yakoub-Agha, I, Carreras, E

“…Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-threatening complication of hematopoietic SCT (HSCT). This review…”
Get full text

Decoding the DC and optical conductivities of disordered MoS2 films: an inverse problem by Duarte, F R, Mukim, S, Molina-Sánchez, A, Rappoport, Tatiana G, Ferreira, M S

“…To calculate the conductivity of a material having full knowledge of its composition is a reasonably simple task. To do the same in reverse, i.e. to find…”
Get full text

Hematopoietic SCT in Europe: data and trends in 2011 by Passweg, J R, Baldomero, H, Bregni, M, Cesaro, S, Dreger, P, Duarte, R F, Falkenburg, J H F, Kröger, N, Farge-Bancel, D, Bobby Gaspar, H, Marsh, J, Mohty, M, Peters, C, Sureda, A, Velardi, A, Ruiz de Elvira, C, Madrigal, A

“…In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) in 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to…”
Get full text

Uptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT–NCI Chronic GVHD Task Force by Duarte, R F, Greinix, H, Rabin, B, Mitchell, S A, Basak, G, Wolff, D, Madrigal, J A, Pavletic, S Z, Lee, S J

“…In 2005, the National Institutes of Health (NIH) consensus conference published a series of papers recommending methods to improve the conduct of clinical…”
Get full text

Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data by Duarte, R F, Shaw, B E, Marín, P, Kottaridis, P, Ortiz, M, Morante, C, Delgado, J, Gayoso, J, Goterriz, R, Martínez-Chamorro, C, Mateos-Mazón, J J, Ramírez, C, de la Rubia, J, Achtereekte, H, Gandhi, P J, Douglas, K W, Russell, N H

“…Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) to enhance stem cell…”
Get full text

Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma by Duarte, R F, Schmitz, N, Servitje, O, Sureda, A

“…There is no standard of care for patients with advanced forms of mycosis fungoides, Sézary syndrome and other less common subtypes of primary cutaneous T-cell…”
Get full text

European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization by Hübel, K, Fresen, M M, Apperley, J F, Basak, G W, Douglas, K W, Gabriel, I H, Geraldes, C, Jaksic, O, Koristek, Z, Kröger, N, Lanza, F, Lemoli, R M, Mikala, G, Selleslag, D, Worel, N, Mohty, M, Duarte, R F

“…The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European…”
Get full text

Development, preliminary usability and accuracy testing of the EBMT ‘eGVHD App’ to support GvHD assessment according to NIH criteria—a proof of concept by Schoemans, H, Goris, K, Durm, R V, Vanhoof, J, Wolff, D, Greinix, H, Pavletic, S, Lee, S J, Maertens, J, Geest, S D, Dobbels, F, Duarte, R F

“…The EBMT Complications and Quality of Life Working Party has developed a computer-based algorithm, the ‘ e GVHD App ’, using a user-centered design process…”
Get full text

Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation by Sánchez-Ortega, I, Patiño, B, Arnan, M, Peralta, T, Parody, R, Gudiol, C, Encuentra, M, Fernández de Sevilla, A, Duarte, R F

“…Posaconazole has been recently approved for primary antifungal prophylaxis in patients with prolonged neutropenia after AML induction chemotherapy and patients…”
Get full text

Early engraftment and full-donor chimerism after single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia by Sánchez-Ortega, I, Arnan, M, Patiño, B, Herrero, M J, Querol, S, Duarte, R F

Get full text

Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 by Sureda, A, Bader, P, Cesaro, S, Dreger, P, Duarte, R F, Dufour, C, Falkenburg, J H F, Farge-Bancel, D, Gennery, A, Kröger, N, Lanza, F, Marsh, J C, Nagler, A, Peters, C, Velardi, A, Mohty, M, Madrigal, A

“…This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current practice and indications for…”
Get full text

Thyroid dysfunction in adult patients late after autologous and allogeneic blood and marrow transplantation by Sánchez-Ortega, I, Canals, C, Peralta, T, Parody, R, Clapés, V, de Sevilla, A F, Duarte, R F

Get full text